公开(公告)号：US06277961B1

公开(公告)日：2001-08-21

申请号：US08272281

申请日：1994-07-08

申请人： Johann Hock ,  Hermann Karges

发明人： Johann Hock ,  Hermann Karges

IPC分类号： A61K3836

CPC分类号： A61L24/001 ,  A61K38/45 ,  A61L24/106 ,  C07K14/75

摘要： A fibrinogen solution which is suitable for use in a tissue adhesive and can be stored at temperatures between +4° C. and +25° C. for at least four weeks without loss of its ability to function, in particular without significant change in consistency and coagulation properties, and a process for the preparation thereof.

摘要翻译： 一种纤维蛋白原溶液，适用于组织粘合剂，可在+ 4°C至+ 25°C之间的温度下储存至少四周，而不会丧失其功能，特别是无明显变化的一致性 凝固性，以及其制备方法。

公开(公告)号：US06204036B1

公开(公告)日：2001-03-20

申请号：US08999702

申请日：1997-12-22

申请人： Hubert Metzner ,  Hermann Karges

发明人： Hubert Metzner ,  Hermann Karges

IPC分类号： C12N996

CPC分类号： C12N9/1044 ,  A61K38/45

摘要： The present invention relates to stable preparation forms of a transglutaminase, for example factor XIII, which, after lyophilization, are readily soluble without turbidity. The preparation froms comprise, in addition to the transglutaminase additives selected from the group consisting of D- and/or L-amino acids other than glycine and arginine, their salts, derivatives and homologs, or dimers or oligomers thereof or mixtures thereof, and sugars or sugar alcohols. The formulations may also comprise surface active agents and/or reducing agents. The invention provides processes for preparing stable protein preparations and to the use of the described stable preparation forms for producing pharmaceuticals which are suitable, for example, for treating diseases which are characterized by F XIII deficiency.

摘要翻译： 本发明涉及转谷氨酰胺酶的稳定制备形式，例如因子XIII，其在冻干后容易溶解而无浊度。 除了甘氨酸和精氨酸以外的选自D-和/或L-氨基酸的转谷氨酰胺酶的添加剂，其制剂还包含其盐，衍生物和同系物或其二聚体或其低聚物或其混合物和糖 或糖醇。 制剂还可以包含表面活性剂和/或还原剂。 本发明提供了制备稳定的蛋白质制剂的方法以及所述稳定的制剂形式用于生产药物的用途，所述药物适用于例如用于治疗以F XIII缺陷为特征的疾病。

公开(公告)号：US4157383A

公开(公告)日：1979-06-05

申请号：US732134

申请日：1976-10-13

申请人： Hans-Harald Sedlacek ,  Roloff Johannsen ,  Fritz Seiler ,  Hermann Karges

发明人： Hans-Harald Sedlacek ,  Roloff Johannsen ,  Fritz Seiler ,  Hermann Karges

IPC分类号： G01N33/49 ,  A61K35/14 ,  A61K38/16 ,  G01N33/53 ,  G01N33/554 ,  A01N1/02 ,  G01N1/00 ,  G01N31/00 ,  G01N33/16

CPC分类号： G01N33/554 ,  A61K35/19 ,  Y10S436/80

摘要： The invention provides tanned thrombocytes, a process for preparing them and a diagnostic agent containing them to make evident antibodies of thrombocytes.

摘要翻译： 本发明提供了鞣制的凝血细胞，其制备方法和含有它们的诊断剂以制备明显的凝血细胞抗体。

公开(公告)号：US5723123A

公开(公告)日：1998-03-03

申请号：US465191

申请日：1995-06-05

申请人： Hermann Karges ,  Horst Naumann

发明人： Hermann Karges ,  Horst Naumann

IPC分类号： A61K38/48 ,  A61K38/00 ,  A61L24/10 ,  A61P7/04 ,  C12N9/74

CPC分类号： C12N9/6429 ,  A61L24/106 ,  C12Y304/21005 ,  A61K38/00 ,  Y10S530/83

摘要： The invention relates to a process for producing a virus free preparation of thrombin, and the use of said virus free concentrate as a pharmaceutical. For example, the invention relates to a process for the production of a purified and virus free preparation of thrombin which comprises adding a soluble salt in a concentration of from 0.5 mol/l up to the saturation limit thereof, said soluble salt having an anion that forms a sparingly-soluble salt or a soluble complex with calcium, to a solution of a prothrombin complex which has been purified on an anion exchanger and subjected to virus inactivation, said solution having a catalytic amount of thrombin present as a result of the purification, the viral inactivation, or added thereafter at a concentration of greater than zero up to 200 units of thrombin per ml of solution.

摘要翻译： 本发明涉及一种生产无病毒的凝血酶制剂的方法，以及使用无病毒浓缩物作为药物。 例如，本发明涉及生产纯化和无病毒的凝血酶制剂的方法，该方法包括加入浓度为0.5mol / l至饱和极限的可溶性盐，所述可溶性盐具有阴离子 与钙离子形成难溶的盐或可溶性络合物，在已经在阴离子交换器上纯化并进行病毒灭活的凝血酶原复合物的溶液中，所述溶液作为纯化结果存在催化量的凝血酶， 病毒灭活，或之后以每毫升溶液大于零至200单位凝血酶的浓度加入。